Respiratory syncytial virus entry and how to block it.,Nature Reviews Microbiology

当前位置： X-MOL 学术 › Nat. Rev. Microbiol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Respiratory syncytial virus entry and how to block it.
Nature Reviews Microbiology ( IF 69.2 ) Pub Date : 2019-04-01 , DOI: 10.1038/s41579-019-0149-x
Michael B Battles ₁ , Jason S McLellan ₂

Affiliation

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease in young children and elderly people. Although the virus was isolated in 1955, an effective RSV vaccine has not been developed, and the only licensed intervention is passive immunoprophylaxis of high-risk infants with a humanized monoclonal antibody. During the past 5 years, however, there has been substantial progress in our understanding of the structure and function of the RSV glycoproteins and their interactions with host cell factors that mediate entry. This period has coincided with renewed interest in developing effective interventions, including the isolation of potent monoclonal antibodies and small molecules and the design of novel vaccine candidates. In this Review, we summarize the recent findings that have begun to elucidate RSV entry mechanisms, describe progress on the development of new interventions and conclude with a perspective on gaps in our knowledge that require further investigation.

中文翻译：

呼吸道合胞病毒进入以及如何阻止它。

呼吸道合胞病毒 (RSV) 是幼儿和老年人下呼吸道疾病的主要原因。尽管该病毒于 1955 年被分离出来，但有效的 RSV 疫苗尚未开发出来，唯一获得许可的干预措施是使用人源化单克隆抗体对高危婴儿进行被动免疫预防。然而，在过去 5 年里，我们对 RSV 糖蛋白的结构和功能及其与介导进入的宿主细胞因子的相互作用的理解取得了实质性进展。这一时期恰逢人们对开发有效干预措施重新产生兴趣，包括分离有效的单克隆抗体和小分子以及设计新型候选疫苗。在这篇综述中，我们总结了最近的研究结果，这些研究结果已经开始阐明 RSV 进入机制，描述了新干预措施的开发进展，并以我们需要进一步调查的知识差距的观点作为结论。

更新日期：2019-02-05

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南